Incyte Corporation is a biopharmaceutical company that discovers, develops, and commercializes proprietary therapeutics primarily in the oncology and hematology sectors. Its main products include JAKAFI (approximately 60% of revenue), PEMAZYRE (about 20%), and ICLUSIG (around 10%), with the remaining revenue coming from clinical-stage products and collaborations. The company targets healthcare providers and institutions that treat cancer and blood disorders. Factors supporting endurance include a strong pipeline of clinical-stage products and established partnerships with larger pharmaceutical companies, while potential limitations include the high costs of drug development and competition from other biopharmaceutical firms.
—
Incyte Corporation is a biopharmaceutical company that discovers, develops, and commercializes proprietary therapeutics primarily in the oncology and hematology sectors. Its main products include JAKAFI (approximately 60% of revenue), PEMAZYRE (about 20%), and ICLUSIG (around 10%), with the remaining revenue coming from clinical-stage products and collaborations. The company targets healthcare providers and institutions that treat cancer and blood disorders. Factors supporting endurance include a strong pipeline of clinical-stage products and established partnerships with larger pharmaceutical companies, while potential limitations include the high costs of drug development and competition from other biopharmaceutical firms.
—
Daily adjusted close
Incyte Corporation is a biopharmaceutical company that discovers, develops, and commercializes proprietary therapeutics primarily in the oncology and hematology sectors. Its main products include JAKAFI (approximately 60% of revenue), PEMAZYRE (about 20%), and ICLUSIG (around 10%), with the remaining revenue coming from clinical-stage products and collaborations. The company targets healthcare providers and institutions that treat cancer and blood disorders. Factors supporting endurance include a strong pipeline of clinical-stage products and established partnerships with larger pharmaceutical companies, while potential limitations include the high costs of drug development and competition from other biopharmaceutical firms.